View from the Thoraxcenter: ESC 24 Hot Line W...

In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE throm ...  Show more

At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricu ...  Show more

In this episode, we delve into the groundbreaking DAMIS trial, exploring the impact of sublingual microcirculation assessment on treatment decisions for ICU patients with shock. We discuss the methodology, findings, and implications of this extensive multicenter study, offering i ...  Show more

How much do beta blockers help after a heart attack, even when the heart’s pumping well? In this episode, we revisit the origins of beta blockers in post-MI care, examine how evidence evolved, and explore the REDUCE-AMI trial, which questions whether beta blockers are still neede ...  Show more

In this episode of the PhysioTutors podcast, Dr. Annina Schmid, a specialist in musculoskeletal physiotherapy and a professor of pain neurosciences at Oxford University, discusses entrapment neuropathies, focusing on conditions like carpal tunnel syndrome and cubital tunnel sy ...

Healthcare professionals are key players in medicines safety but they often lack the time or knowledge to report adverse drug reactions. To change that, we need to urgently rethink how we teach pharmacovigilance, argues Michael Reumerman from Amsterdam University Medical Cente ...